FY2025 · ended Dec 31, 2025 · Revenue $409,657, -59.0% YoY · Filed Mar 10, 2026
Medicinova, Inc. (MNOV) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $409,657 and a net loss of $12.0 million. Free cash flow was -$9.8 million. As of Jun 30, 2026 it held $25.4 million in cash and investments and $117,038 in total debt.
Revenue (TTM)
$920,481
Net income (TTM)
$-10.75M
+9.0% vs year-ago TTM
Operating cash flow (TTM)
$-9.11M
+9.4% vs year-ago TTM
Free cash flow (TTM)
$-9.12M
EPS (TTM)
$-0.22
+9.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
49.22M
+0.4% vs prior year
Net cash
$25.30M
as of Jun 30, 2026
Operating margin
-1287.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNOV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1226616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $409,657 | — | $1.0M | — | $4.0M |
| Operating income | -$13.3M | -$12.7M | -$9.9M | -$14.6M | -$10.2M |
| Net income | -$12.0M | -$11.0M | -$8.6M | -$14.1M | -$10.1M |
| Diluted EPS | -$0.24 | -$0.23 | -$0.17 | -$0.29 | — |
| Operating cash flow | -$9.8M | -$10.6M | -$7.4M | -$12.9M | -$9.4M |
| Free cash flow | -$9.8M | -$10.6M | -$7.5M | -$12.9M | -$9.4M |
| Total assets | $45.6M | $55.9M | $66.3M | $74.2M | $87.4M |
| Total liabilities | $4.0M | $3.4M | $3.9M | $3.9M | $3.7M |
| Stockholders' equity | $41.6M | $52.5M | $62.4M | $70.2M | $83.7M |
| Cash and investments | $30.8M | $40.4M | $51.0M | $58.5M | $71.4M |
| Total debt | $211,460 | $405,229 | $626,586 | $681,124 | $826,639 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 28, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Agreement ended
|
Sep 2, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 19, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 23, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 879 Medicinova, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.